Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
|Articles|July 25, 2022
Daily Medication Pearl: Piperacillin and Tazobactam (Zosyn)
Author(s)Saro Arakelians, PharmD
Piperacillin and tazobactam (Zosyn) is indicated for treatment of intra-abdominal infections, skin and skin structure infections, female pelvic infections, community-acquired pneumonia, and nosocomial pneumonia.
Advertisement
Medication Pearl of the Day: Piperacillin and Tazobactam (Zosyn)
Indication: Piperacillin and tazobactam (Zosyn) is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of intra-abdominal infections, skin and skin structure infections, female pelvic infections, community-acquired pneumonia, and nosocomial pneumonia.
Insight:
- Dosing: The usual daily dose of Zosyn for adults is 3.375 g every 6 hours, totaling 13.5 g.
- Dosage forms: Zosyn for injection 2.25 g, 3.375 g, and 4.5 g lyophilized powder for reconstitution in single-dose vials and 40.5 g lyophilized powder for reconstitution in pharmacy bulk vials.
- Adverse events: The most common adverse reactions (incidence >5%) are diarrhea, constipation, nausea, headache, and insomnia.
- Mechanism of action: Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. In vitro, piperacillin is active against a variety of Gram-positive and Gram-negative aerobic and anaerobic bacteria. Tazobactam sodium has little clinically relevant in vitro activity against bacteria due to its reduced affinity to penicillin-binding proteins.
Source:
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5